FindTrial
Sign In

A randomized, double-blind study of a combination of amlodipine and irbesartan in patients with essential hypertension who insufficiently responded to irbesartan once daily

A randomized, double-blind study of a combination of amlodipine and irbesartan in patients with essential hypertension who insufficiently responded to irbesartan once daily

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220753
Enrollment
Unknown
Registered
2009-06-17
Start date
2009-06-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

investigational material(s) Generic name etc : amlodipine, irbesartan INN of investigational material : Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investigational

Sponsors

Dainippon Sumitomo Pharma Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with essential hypertension who meet one of the following criteria a) Patients who are taking antihypertensive drugs b) Patients who are not taking any antihypertensive drugs and whose seated systolic blood pressure (SBP) is >=160 mmHg or whose diastolic blood pressure (DBP) is >=100 mmHg

Exclusion criteria

Exclusion criteria: Patients with renal, hepatic or heart desease

Design outcomes

Primary

MeasureTime frame
Efficacy: Change in trough BP from baseline Efficacy: Populations of patients whose trough BPs successively reached the target level—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026